GLP-1 Agonists Tied to Lower Mortality in Severe Psychiatric Disorders

A large observational study found that adults with serious mental illness who started GLP-1 receptor agonists had a 24% lower risk of death over four years compared with those starting SGLT2 inhibitors. The benefit was mainly due to fewer cardiovascular events, including heart attacks and strokes. The findings suggest these drugs might help reduce the well-known lifespan gap for people with serious psychiatric conditions.